Should SGLT2 and GLP-1 drugs be combined for type 2?

Combining GLP-1 receptor agonist exenatide and SGLT2-inhibitor dapagliflozin reduces HbA1c and bodyweight in patients with type 2 diabetes inadequately controlled on metformin, the first randomised controlled trial into the combination shows.

The AstraZeneca-funded DURATION-8 study randomised 695 patients to a dapagliflozin/exenatide combination  or placebo combinations with either drug, and followed them for 28 weeks.